

# UC San Diego

## UC San Diego Previously Published Works

### Title

Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath

### Permalink

<https://escholarship.org/uc/item/1r94b58x>

### Journal

Clinical Chemistry and Laboratory Medicine, 58(5)

### ISSN

1434-6621

### Authors

Hubbard, Jacqueline A  
Smith, Breland E  
Sobolesky, Philip M  
et al.

### Publication Date

2020-05-01

### DOI

10.1515/cclm-2019-0600

Peer reviewed

Jacqueline A. Hubbard\*, Breland E. Smith, Philip M. Sobolesky, Sollip Kim, Melissa A. Hoffman, Judith Stone, Marilyn A. Huestis, David J. Grelotti, Igor Grant, Thomas S. Marcotte and Robert L. Fitzgerald

# Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath

<https://doi.org/10.1515/cclm-2019-0600>

Received June 13, 2019; accepted August 21, 2019

## Abstract

**Background:** The widespread availability of cannabis raises concerns regarding its effect on driving performance and operation of complex equipment. Currently, there are no established safe driving limits regarding  $\Delta^9$ -tetrahydrocannabinol (THC) concentrations in blood or breath. Daily cannabis users build up a large body burden of THC with residual excretion for days or weeks after the start of abstinence. Therefore, it is critical to have a sensitive and specific analytical assay that quantifies THC, the main psychoactive component of cannabis, and multiple metabolites to improve interpretation of cannabinoids in blood; some analytes may indicate recent use.

**Methods:** A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed to quantify THC, cannabitol (CBN), cannabidiol (CBD), 11-hydroxy-THC (11-OH-THC), ( $\pm$ )-11-nor-9-carboxy- $\Delta^9$ -THC (THCCOOH), (+)-11-nor- $\Delta^9$ -THC-9-carboxylic acid

glucuronide (THCCOOH-gluc), cannabigerol (CBG), and tetrahydrocannabivarin (THCV) in whole blood (WB). WB samples were prepared by solid-phase extraction (SPE) and quantified by LC-MS/MS. A rapid and simple method involving methanol elution of THC in breath collected in SensAbues® devices was optimized.

**Results:** Lower limits of quantification ranged from 0.5 to 2  $\mu\text{g/L}$  in WB. An LLOQ of 80 pg/pad was achieved for THC concentrations in breath. Calibration curves were linear ( $R^2 > 0.995$ ) with calibrator concentrations within  $\pm 15\%$  of their target and quality control (QC) bias and imprecision  $\leq 15\%$ . No major matrix effects or drug interferences were observed.

**Conclusions:** The methods were robust and adequately quantified cannabinoids in biological blood and breath samples. These methods will be used to identify cannabinoid concentrations in an upcoming study of the effects of cannabis on driving.

**Keywords:** breath; cannabis; LC-MS/MS; mass spectrometry; THC; whole blood.

\*Corresponding author: **Jacqueline A. Hubbard**, PhD, Department of Pathology, University of California, 10300 Campus Point Drive, San Diego, CA 92121, USA, E-mail: jachubbard@gmail.com, jahubbard@ucsd.edu. <https://orcid.org/0000-0003-4092-7153>

**Breland E. Smith:** Insource Diagnostics, Monrovia, CA, USA

**Philip M. Sobolesky:** Department of Pathology and Laboratory Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA

**Sollip Kim:** Department of Laboratory Medicine, Inje University Ilsan Paik Hospital, Ilsan Seo-gu, Goyang, Republic of Korea

**Melissa A. Hoffman and Robert L. Fitzgerald:** Department of Pathology, University of California, San Diego, CA 92121, USA

**Judith Stone:** University of California, San Francisco Medical Center, Laboratory Medicine, Parnassus Chemistry, San Francisco, CA, USA

**Marilyn A. Huestis:** The Lambert Center for the Study of Medicinal Cannabis and Hemp, Institute for Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA, USA

**David J. Grelotti, Igor Grant and Thomas S. Marcotte:** Department of Psychiatry, University of California, San Diego, CA, USA

## Introduction

Cannabis is available for medicinal purposes in many states. An expert review from the National Academies of Science, Engineering, and Medicine (2017) found that there was conclusive or substantial evidence for the use of cannabis and/or cannabinoids for certain conditions (e.g. chronic pain, emesis, spasticity due to multiple sclerosis), with mixed or limited evidence for many other conditions [1]. Whole-plant-based and non-prescription products still dominate the market, and cannabis as a medicine remains controversial [2]. Furthermore, as more cannabinoid pharmacotherapies are identified, the need for assays to accurately measure cannabinoid concentrations will increase.

Support for recreational legalization of cannabis is growing [3]. With this comes concerns regarding the

impact of acute cannabis use on safety and driving performance. According to the National Roadside Study of Alcohol and Drug Use by Drivers,  $\Delta^9$ -tetrahydrocannabinol (THC) was the most frequently detected illicit drug in drivers [4]. THC impairs learning [5] and driving-related functions, such as reaction time and tracking ability [6]. This impairment is dose-dependent and can last for several hours [6, 7].

There are several challenges in determining impairment while driving under the influence of cannabis (DUI/C). The time between a traffic stop or motor vehicle crash and a blood draw is typically 1.5–4.5 h [8, 9], while THC blood concentrations are >90% cleared within 1.4 h [10]. Therefore, measured THC concentrations likely will not reflect concentrations at the time of the incident. Blood is currently the standard matrix for toxicological interpretations but a non-invasive matrix such as oral fluid or breath may enable more timely roadside collections. In addition, blood THC concentrations do not correlate with cognitive effects [11]. Maximum THC concentrations are typically observed within 15 min of the start of smoking but the subjective “high” and objective impairment can last for several hours [12]. Finally, the clearance rate of THC depends on the frequency of cannabis use. THC can be detected (LLOQ 0.25–0.5  $\mu\text{g/L}$ ) for several weeks in the blood of chronic users [13], but only for days in occasional users [14].

Given the tenuous relationship between blood THC concentrations and impairment, it may prove fruitful to examine additional THC metabolites. We thus optimized and validated a liquid chromatography tandem mass spectrometry (LC-MS/MS) method that could simultaneously quantify multiple cannabinoids and metabolites, including THC, 11-hydroxy-THC (11-OH-THC), ( $\pm$ )-11-nor-9-carboxy- $\Delta^9$ -THC (THCCOOH), (+)-11-nor- $\Delta^9$ -THC-9-carboxylic acid glucuronide (THCCOOH-gluc), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), and tetrahydrocannabinol (THCV), in whole blood (WB) in a single 5-min run. Furthermore, the detection of THC from breath specimens was validated.

## Materials and methods

### Chemicals, materials, and blank matrices

Stocks of 1 mg/mL of CBD, THC, CBN, 11-OH-THC, CBG, THCV, THCA-A, and THCCOOH- $D_3$  as well as 100  $\mu\text{g/mL}$  solutions of THCCOOH, THCCOOH-gluc, CBD- $D_3$ , THC- $D_3$ , CBN- $D_3$ , and 11-OH-THC- $D_3$  were purchased from Cerilliant (Round Rock, TX, USA). A 10- $\mu\text{g/mL}$  THC-gluc stock was obtained from ElSohly (Oxford, MS, USA).

Optima LC/MS grade acetonitrile, methanol, 2-propanol, formic acid (FA), and ammonium acetate were obtained from Fisher Scientific (Hampton, NH, USA). Oasis PRiME HLB 96-well solid-phase extraction (SPE) plates with 30 mg sorbent/well, 96-well collection plates, quick-load glass inserts, silicone/PTFE-treated 96-well square plug cap mats, and amber max recovery autosampler vials were acquired from Waters (Milford, MA, USA). Borosilicate glass tubes were from Fisher Scientific and 18.2 M $\Omega$ -cm water was dispensed from a Siemens PureLab Ultra purification system.

Blank WB was created by mixing acid citrate dextrose (ACD)-packed red blood cells with ABO-compatible plasma and confirming the absence of detectable cannabinoids. Breath matrix consisted of an unused SensAbues<sup>®</sup> electret filter material (“pad”) cut into 28 cm<sup>2</sup> squares to match the intake surface area of the SensAbues<sup>®</sup> collection device.

### Preparation of standards

Calibrators were prepared in methanol using class A glass volumetric pipettes and glass volumetric flasks. All stock and working calibrators were stored at  $-20^\circ\text{C}$ .

**Whole blood standards:** Concentrated methanolic stocks of 10,000  $\mu\text{g/L}$  (lacking THC-gluc) and 1000  $\mu\text{g/L}$  containing CBN, CBD, THC, 11-OH-THC, CBG, THCV, THCA-A, THCCOOH, THCCOOH-glu, and THC-gluc were prepared by mixing and diluting the commercially available standards. Parallel dilutions of the 1000- $\mu\text{g/L}$  stock were used to formulate the remainder of the working standards in methanol. Final concentrations were 10,000 (lacking THC-gluc), 1000, 500, 100, 20, 10, and 5  $\mu\text{g/L}$ . Working standards were added to blank WB at a 1:10 dilution to give final concentrations of 1000, 100, 50, 10, 2, 1, and 0.5  $\mu\text{g/L}$ , respectively.

**Breath standards:** Parallel dilutions of a 100- $\mu\text{g/mL}$  stock of THC created working standards at concentrations of 10,000, 4000, 100, 20, and 5  $\mu\text{g/L}$  in methanol. To create a calibration curve, 25  $\mu\text{L}$  of the 5-, 20-, 4000-, and 10,000- $\mu\text{g/L}$  standards and 50  $\mu\text{L}$  of the 10,000- $\mu\text{g/L}$  standard were pipetted directly onto unused SensAbues<sup>®</sup> pads for final amounts of 125, 500, 100,000, 250,000, and 500,000 pg/pad, respectively.

**Internal standard (IS):** A concentrated deuterium-labeled stock solution was prepared by mixing and diluting THC- $D_3$ , THCCOOH- $D_3$ , CBD- $D_3$ , CBN- $D_3$ , and 11-OH-THC- $D_3$  in methanol. Final concentrations were 100  $\mu\text{g/L}$  for all compounds except CBD- $D_3$ . CBD- $D_3$  was added at 10  $\mu\text{g/L}$  because 100  $\mu\text{g/L}$  caused interference, presenting as a shoulder on the CBG qualifier ion peak (Supplementary Figure 1).

The IS for CBN, CBD, THC, 11-OH-THC, and THCCOOH were the corresponding deuterated compounds. CBD- $D_3$  was the IS for CBG and THCA-A. 11-OH-THC- $D_3$  was the IS for THC-gluc and THCV. THCCOOH- $D_3$  was the IS for THCCOOH-gluc due to the presence of a double peak in THCCOOH-gluc- $D_3$  (Supplementary Figure 2).

IS was added to WB at a 1:10 dilution, resulting in final concentrations of 1  $\mu\text{g/L}$  for CBD- $D_3$  and 10  $\mu\text{g/L}$  for all others. For breath analysis, only THC was monitored. Twenty-five microliters of IS was spiked into a clean SensAbues<sup>®</sup> device containing a pad for a final concentration of 250 pg THC- $D_3$ /pad.

## Preparation of quality control (QC) material

QC working stocks were made by parallel dilution of a 1000- $\mu\text{g/L}$  stock, as described for the calibrators, except using different lots for all compounds except for THC-gluc where only one lot was commercially available. At least one set of QCs at three different concentrations were included in every batch. The concentration of WB working QCs after validation were 33.3, 100, and 833  $\mu\text{g/L}$ . These were diluted 1:10 into WB for final concentrations of 3.3, 10.0, and 83.3  $\mu\text{g/L}$ , respectively. The concentration of breath QC stocks were 6.0, 60.0, and 6000  $\mu\text{g/L}$ . Pads were spiked with 25  $\mu\text{L}$  for final concentrations of 150, 1500, and 150,000 pg THC/pad, respectively.

## Sample collection

Participants provided blood and breath samples as part of a larger study examining cannabis-related driving impairment approved by the University of California, San Diego Human Research Protections Program (IRB # 160641). Consenting volunteers ( $n=5$ ) were given a joint containing 13.4% THC procured from the National Institute on Drug Abuse Drug Supply Program. Blood and breath samples were collected prior to and  $\sim 10$  min after smoking cessation. Venous blood was drawn from the arm in sodium fluoride (NaF) vacutainer tubes. WB was transferred to cryovials and stored at  $-20$  °C for up to 3 months until analysis [15]. Breath samples were collected over a 3-min period using a SensAbues<sup>®</sup> device containing a pad to trap aerosol breath (AB, Sweden). Mouthpieces were discarded, and the devices containing collection pads were capped and stored at  $-20$  °C for up to 6 months until analysis [16].

## Sample processing

**Whole blood:** Calibrators and QCs were prepared by fortifying calibrators or QCs (20  $\mu\text{L}$ ) into 200  $\mu\text{L}$  blank WB in borosilicate tubes. Blank and volunteer WB (200  $\mu\text{L}$ ) were added to corresponding tubes and fortified with 20  $\mu\text{L}$  methanol. IS (20  $\mu\text{L}$ ) was added to all tubes except one of two blank tubes, resulting in a “blank” and “blank + IS”. Proteins were precipitated by adding 500  $\mu\text{L}$  ice-cold acetonitrile with 0.1% FA dropwise into each tube while vortexing. Samples were centrifuged at  $1962 \times g$  for 10 min. Supernatants were poured into new tubes, diluted with 1.1 mL 18 M $\Omega$  water, and loaded onto an SPE plate. SPE was performed using a positive pressure apparatus (Waters Positive Pressure-96). Samples were loaded onto the sorbent material at low pressure (10 psi) for 5 min. Next, samples were washed twice with 500  $\mu\text{L}$  25% methanol. Samples were eluted twice with 100  $\mu\text{L}$  90:10 acetonitrile:isopropanol and twice with 100  $\mu\text{L}$  50:50 acetonitrile:methanol with 2% FA into a 96-well plate with glass inserts. Samples were dried with 40 °C N<sub>2</sub> gas (Porvair Sciences MiniVap), reconstituted in 200  $\mu\text{L}$  50% acetonitrile with 0.1% FA, and capped with a cap mat. Plates were vortexed (Multi-tube vortexer, Fisher Scientific), centrifuged at  $1962 \times g$  for 10 min, and loaded into an autosampler.

**Breath:** A pad was placed inside clean SensAbues<sup>®</sup> devices for the calibrators, QCs, blank, and blank + IS. These were placed on top of borosilicate tubes with the device neck inside each tube. Devices from volunteers were also placed into tubes. Working IS (25  $\mu\text{L}$ ) was

added to each device except for the blank. Next, QCs and calibrators were added to the corresponding devices. The devices were dried at room temperature for 10 min. Pads were pushed into the neck of the device with a clean wooden applicator. Samples were eluted twice with 2.5 mL of methanol over 10 min. Residual methanol was squeezed from the device using a pipette bulb affixed on top of each device. Samples were mixed and 1.5 mL was transferred to each of the two max recovery vials (one for processing, one for storage). Vials were dried under nitrogen at 60 °C for 25 min, re-suspended with 200  $\mu\text{L}$  50% acetonitrile with 0.1% FA, and loaded into the autosampler.

## Liquid chromatography (LC)

LC was performed in a similar manner to a previously described method [17]. Briefly, a Waters Acquity i-class UPLC equipped with a column heater (40 °C) was utilized. Full-loop 10  $\mu\text{L}$  injections were separated on a BEH C18 column (2.1  $\times$  50 mm, 1.7  $\mu\text{m}$  particles) with a BEH C18 VanGuard pre-column (2.1  $\times$  5 mm, 1.7  $\mu\text{m}$  particles). Separation was performed with a 0.4 mL/min flow rate using mobile phase A (MPA) consisting of 5 mM ammonium formate with 0.1% FA and mobile phase B (MPB) consisting of acetonitrile with 0.1% FA. The method starts with 50% MPB for 30 s followed by a 3.5-min linear gradient increasing to 90% MPB. The column was washed for 15 s at 90% MPB and then re-equilibrated with initial conditions for 45 s. The total run time was 5 min/sample.


## Mass spectrometry (MS)

As described previously [17], the LC system was coupled to a Waters TQS-micro tandem quadrupole MS with an electrospray ionization source. All compounds were analyzed in a positive ionization mode with the exception of THCCOOH-gluc, which required negative ionization. Transition ions were collected by scheduled multiple reaction monitoring using previously described parameters [17]. Concentrations were calculated by dividing quantifier transition ion peak areas by IS peak areas and quantified against the calibration curve included with each batch. A representative chromatogram of all quantifier ions and deuterated ISs from a WB calibrator is displayed in Figure 1.

## Method validation

Method validation was done in accordance with the Clinical and Laboratory Standards Institute (CLSI) C62-A guidelines for LC-MS/MS. Experimental design was modified from the CLSI EP05-A3 guidelines for the evaluation of the precision of quantitative measurement procedures.

**Sensitivity and detection criteria:** The LLOQ was determined as the lowest concentration with an acceptable peak shape, signal-to-noise ratio ( $S/N \geq 10$ ), accuracy (% bias) and imprecision (% CV) within 20%, and a quantifier-to-qualifier ratio within 20% of the mean calibrator ratio. Peaks for compounds with a corresponding deuterated IS (THC, 11-OH-THC, THCCOOH, CBN, and CBD) were identified based on a relative RT of  $1.01 \pm 0.02$ . Compounds without a corresponding



**Figure 1:** Total ion chromatogram of a 10- $\mu\text{g/L}$  calibrator in whole blood. Each peak is labeled with the corresponding cannabinoid(s). Signal intensity (y-axis) is plotted against retention time (x-axis). All were chromatographically resolved with the exception of CBG, CBD, and THC.

deuterated IS were identified by RTs matching within  $\pm 0.02$  min of the calibrators. An exception to this was THCCOOH-gluco, which exhibited an RT shift of  $-0.06$  min in biological samples compared to commercially available calibrators due to isomeric differences (Supplementary Figure 2).

**Linearity:** Calibration curves were established with five to seven calibrators per compound in WB and five calibrators in breath. A line was fitted using a least-squares regression with a  $1/x$  weighting factor. Linearity was validated with five replicates of all calibrators analyzed on different days. Acceptability criteria required that all calibrators except the LLOQ quantify within  $\pm 15\%$  of the target concentration; the LLOQ was required to quantify within  $\pm 20\%$ . Imprecision criteria for all calibrators was  $\leq 20\%$  CV and the coefficient of determination ( $R^2$ ) was required to be  $\geq 0.995$ . For each batch, a maximum of one calibrator was allowed to be excluded from the curve for cause.

**QC bias and imprecision:** The QC bias and inter-day imprecision were determined using two concentrations of QC each day for 20 days ( $n = 20$  per QC). The intra-day imprecision was assessed with six replicates of two QC concentrations within the same run. Imprecision was required to be  $\leq 20\%$ . QC values were reassigned based on mean concentrations obtained during validation.

**Process efficiency and matrix effects:** The total process efficiency (PE) was determined by comparing area counts of blank matrix fortified with low QC, and IS prior to sample processing were compared to area counts of “neat” sample containing low QC and IS in the elution solvent [18]. At least three replicates of three concentrations across the analytical measuring range were used for both sets. For WB, this was done in both ACD and NaF blood to determine if calibrators created using ACD blood would accurately quantify analytes in NaF blood.

WB in ACD and NaF tubes and breath samples were collected from 10 drug-free volunteers. The matrix effect was quantified by

spiking samples with the low QC prior to processing. Recovered concentrations were then compared to the low QC mean established in validation.

**Drug interferences:** The blank matrix fortified with low QC was spiked with either methanol or one of five pools containing supra-physiological concentrations of 10 commonly prescribed or abused drugs [17]. Lack of interference was defined as  $\leq 20\%$  bias in the quantification of the low QC concentration in the presence of the different potential interferents.

**Autosampler stability and carryover:** The stability of samples stored in the autosampler ( $10^\circ\text{C}$ ) was assessed by comparing the concentrations of QCs and volunteer samples obtained during the initial run and those obtained 24, 48, 72, and 96 h later. Samples were considered stable if the concentration was quantified within 20% of the initial concentration.


Carryover was investigated by injecting a blank + IS before and immediately after the highest calibrator. The blank was visually inspected for any identifiable peak. The criteria for acceptable carryover was a concentration  $< 20\%$  of the lowest calibrator.

## Results

### Limits of detection, accuracy, and linearity

A representative chromatogram of each reported compound at the LLOQ is shown (Figure 2). The LLOQs, ULOQs, calibration accuracy range, and mean  $R^2$  value are listed in Table 1. LLOQs in WB ranged from 0.5 to 2  $\mu\text{g/L}$ . The LLOQ for THC in breath was 80 pg/pad. THC-gluco and THCA-A in WB did not pass the validation criteria (see following





**Figure 2:** Representative extracted ion chromatograms of the quantifier transition ions for all cannabinoids at the lower limit of quantification.

The percent signal intensity (y-axis) is plotted against retention time (x-axis). The cannabinoids shown, from left to right, include THCCOOH-gluc, 11-OH-THC, THCCOOH, CBG, CBD, THCv, CBN, and THC in whole blood, and THC in breath. The lower limit of quantification ranged from 0.5 to 2 µg/L in blood and was 80 pg/pad in breath.

**Table 1:** Linearity and limits of quantification.

Cannabinoid	LLOQ, µg/L	ULOQ, µg/L	Calibrator % accuracy range	Mean R <sup>2</sup> of calibration curve
THCCOOH-gluc	2.0	1000	93–108	0.9997
11-OH-THC	1.0	100	88–110	0.9996
THCCOOH	1.0	1000	92–109	0.9997
CBG	1.0	100	90–111	0.9993
CBD	0.5	100	91–110	0.9988
THCv	0.5	100	86–112	0.9990
CBN	0.5	1000	91–114	0.9997
THC (blood)	0.5	1000	83–111	0.9992
THC (breath)	80 pg/pad	500,000 pg/pad	85–114	0.9985

text). For all other compounds, linearity throughout the measurable range was validated.

## QC bias and imprecision

All QCs were within 8% of the target concentration except for THCv in WB, which exhibited a 14.8% bias for QC2 (Table 2). The intra-day imprecision ranged from 1 to 8.6% for all cannabinoids. The inter-day imprecision was slightly higher for most compounds and ranged from 4.3 to 12.5%.

## Process efficiency

PE was determined in ACD and NaF anticoagulated blood (Table 3). Similar efficiencies were obtained in both blood types with the exception of CBN and THC (>20% difference). Their corresponding ISs showed similar differences between the two blood types and therefore corrected for matrix effects. However, CBN-D<sub>3</sub> and THC-D<sub>3</sub> could not be used as an IS for any other compound due to this issue. Similar total PEs were observed between THC and THC-D<sub>3</sub> in the breath method (Table 3).

**Table 2:** QC bias and imprecision.

Cannabinoid	Bias, %		Intra-day precision, % CV		Inter-day precision, % CV	
	QC 1	QC 2	QC 1	QC 2	QC 1	QC 2
THCCOOH-gluc	-1.7	-4.9	8.6	4.3	6.8	8.1
11-OH-THC	-5.1	-3.3	4.1	3.1	7.8	5.6
THCCOOH	-2.4	-3.1	5.0	3.6	6.1	5.8
CBG	-6.2	-7.9	4.4	1.0	5.5	12.5
CBD	-5.4	-0.8	3.8	3.0	6.0	4.3
THCV	-5.1	14.8	2.3	4.5	6.0	7.1
CBN	-4.2	-1.1	5.4	2.6	6.5	4.9
THC (blood)	-1.8	1.9	2.4	2.0	6.9	5.2
THC (breath)	-5.1	-7.7	4.7	7.5	8.9	5.0

Target concentrations for whole blood: QC 1 = 3.3 µg/L and QC 2 = 3.3 µg/L. Target concentrations for breath: QC 1 = 150 pg/pad and QC 2 = 1500 pg/pad.

**Table 3:** Process efficiency for acid citrate dextrose (ACD) blood, sodium fluoride (NaF) blood, and breath.

Cannabinoid	Recovery, %		% Difference (NaF – ACD)
	ACD	NaF	
Cannabinoid (blood)			
THCCOOH-gluc	67.9	70.8	2.9
11-OH-THC	67.4	81.0	13.6
11-OH-THC-D <sub>3</sub>	59.4	70.2	10.8
THCCOOH	76.1	80.9	4.8
THCCOOH-D <sub>3</sub>	65.7	66.0	0.3
CBG	62.1	68.1	6.0
CBD	67.5	77.6	10.1
CBD-D <sub>3</sub>	60.7	66.4	5.7
THCV	78.4	86.6	8.2
CBN	39.5	69.0	29.5
CBN-D <sub>3</sub>	35.6	61.2	25.6
THC	41.1	79.7	38.6
THC-D <sub>3</sub>	33.3	68.4	35.1
Cannabinoid (breath)			
THC		52.0	–
THC-D <sub>3</sub>		61.5	–

## Matrix effects and drug interferences

To assess the matrix effect, samples were spiked with 3.3 µg/L QC and the recovered concentration was compared to the expected values (Table 4). All biases were <20% with the exception of THC-gluc (–21%) and THCA-A (53%) in blood. Due to this interference and a lack of deuterated IS to correct for it, THC-gluc and THCA-A failed validation. Breath samples spiked with 150 pg/pad did not show a matrix effect. No drug interferences were observed (Table 5).

**Table 4:** Quantitative matrix interference between authentic samples and the corresponding blank matrix.

Cannabinoid	Mean % bias
THCCOOH-gluc	6
THC-gluc	–21
11-OH-THC	12
THCCOOH	5
CBG	–1
CBD	7
THCV	17
CBN	9
THC (blood)	8
THCA-A	53
THC (breath)	7

## Autosampler stability and carryover

THC concentrations in processed breath remained stable for at least 96 h in the autosampler; all samples were re-quantified within 20% of the initial concentration. In WB, all cannabinoids were stable for at least 24 h. At 48 h post-extraction, all compounds except THCCOOH-gluc were stable. By 72 h, several compounds, including CBN, THC, and THCCOOH-gluc, were not quantifiable. Methanolic calibrators and QCs were stable at –20 °C for at least 2 years.

No carryover was observed for any cannabinoid in either matrix.

## Authentic sample quantification before and after smoking

Concentrations of all compounds were measured prior to and after smoking in five volunteers as proof of concept that our method accurately measures THC and its metabolites in authentic samples (Table 6). THCCOOH and THCCOOH-gluc were detectable in WB of four of the five volunteers prior to smoking. After smoking, all cannabinoids except THCV and CBD were detected in WB. All participants had detectable levels of THC in breath after smoking.

## Discussion

We describe a robust, validated method for the quantification of eight cannabinoids in WB and THC in breath. The WB method expands on previously published approaches [19–24] and includes additional cannabinoids in a single

**Table 5:** Drug interferences expressed as percent bias compared to the methanol-spiked QC.

Cannabinoid	Drug pool 1	Drug pool 2	Drug pool 3	Drug pool 4	Drug pool 5
THCCOOH-gluc	8.3	-1.0	-2.8	8.3	2.8
THC-gluc	15.9	5.3	6.8	11.4	9.1
11-OH-THC	9.4	6.5	9.4	9.4	12.5
THCCOOH	2.7	2.2	-8.1	-2.7	-5.4
CBG	16.7	-5.3	16.7	13.3	13.3
CBD	20.0	-3.1	13.3	13.3	13.3
THCV	-2.1	-7.9	-6.3	-8.3	0.0
CBN	6.1	-1.1	6.1	9.1	15.2
THC (blood)	11.8	-2.2	8.8	8.8	8.8
THCA-A	-2.1	-7.9	-12.1	6.1	6.1
THC (breath)	7.9	6.2	8.4	-5.4	6.4

**Table 6:** Proof-of-concept cannabinoid concentrations before and after smoking a joint containing 13.4% THC.

Cannabinoid	Prior to smoking, µg/L		Ten minutes after smoking cessation, µg/L	
	Median	Range	Median	Range
THCCOOH-gluc	21.8	<LLOQ–275	24.7	<LLOQ–235
11-OH-THC	<LLOQ	<LLOQ–1.8	3.0	1.5–12.1
THCCOOH	9.8	<LLOQ–54.5	26.7	11–64.7
CBG	<LLOQ	<LLOQ	1.1	<LLOQ–1.6
CBD	<LLOQ	<LLOQ	<LLOQ	<LLOQ
THCV	<LLOQ	<LLOQ	<LLOQ	<LLOQ
CBN	<LLOQ	<LLOQ	4.9	1.1–7.3
THC (blood)	<LLOQ	<LLOQ–3.9	60.9	10.3–78.4
THC (breath)	<LLOQ	<LLOQ–242 pg/pad	163,000 pg/pad	88,595–279,000 pg/pad

5-min run. The breath method offers a simplified, yet accurate approach to process and quantify THC in breath. Our method quantifies THC and several cannabis metabolites in authentic human blood and breath samples. Together, these methods will aid in future cannabis therapeutic efficacy and driving safety studies.

There is no agreement in the blood THC concentration that defines impairment. This contrasts with blood alcohol concentrations (BAC), for which concentrations as low as 0.05%–0.08% are strongly correlated with impairment [25]. Portable breath analyzers are used as preliminary screens to estimate BAC. Given the invasive nature of blood draws and frequent collection delays, there is increasing interest in the detection of THC in an easily collected matrix, such as breath. THC concentrations in breath indicate recent use and may correlate with blood concentrations [26]. Furthermore, breath concentrations are correlated with physiological changes such as change in pulse rate and pupil diameter seen after smoking [27]. Therefore, breath could serve as an alternative matrix for roadside impairment assessment.

Other groups published methods to detect cannabinoids in breath. Beck and colleagues offered a method that required a 1-h incubation in a thermostatic bath at 37 °C combined with two extraction procedures [28]. Here, we offered a simplified method that reduced turnaround time. A more recent method using azo coupling derivatization offers sensitive detection with an LLOQ of 0.5 pg THC/mL [29]. Finally, a previously published method using the SensAbues® device measured THC concentrations in breath ranging from 50.7 to 1170 pg/pad at a mean time of 53 min after smoking [16]. We observed much higher concentrations ( $\geq 88,595$  pg/pad), likely because samples were collected ~10 min after smoking was completed, when THC concentrations in breath would be near maximal. This difference is unlikely due to oral fluid contribution because retention of oral fluid by the trapping baffles integrated into the mouthpiece of the SensAbues® device was previously confirmed by the lack of  $\alpha$ -amylase in samples eluted directly from the pad while kept inside the device [30]. Our goal was to validate a method with a quicker and simpler procedure that accurately quantifies THC in breath. Our method offers a straightforward



extraction protocol that does not require disassembling SensAbues® breath devices or derivatization while still achieving good analytical sensitivity.

During validation, THCA-A and THC-gluc exhibited significant matrix effects. Despite this, others have quantified THCA-A [31] and THC-gluc [32] using LC-MS/MS in WB. Sorensen and colleagues removed interfering phospholipids by filtration using a hybrid SPE-phospholipid plate containing a stationary phase with bonded zirconia and successfully quantified THCA-A [31]. Disposable pipette extraction, instead of SPE, was previously used to extract and quantify THC-gluc in WB [32].

We noted an RT shift in THCCOOH-gluc peaks between human samples and calibrators during validation (Supplementary Figure 2). Biological THCCOOH-gluc eluted at 1.28 min and the analytical standard at 1.22 min. The THCCOOH-gluc-D<sub>3</sub> available from Cerilliant (T-080, (±)-cis-11-Nor-9-carboxy-Δ<sup>9</sup>-THC-D<sub>3</sub>-glucuronide) produced two isomeric chromatographic peaks. When THCCOOH-gluc-D<sub>3</sub> was base hydrolyzed, it resulted in the formation of THCCOOH-D<sub>3</sub> with a shifted RT compared to the THCCOOH-D<sub>3</sub> standard. However, when THCCOOH-gluc was hydrolyzed, the resulting RT of THCCOOH matched its respective standard. Therefore, the biological form of THCCOOH-gluc is likely a different isomer than the commercially available form [33].

The WB and breath methods developed here facilitate efficient detection of multiple cannabinoid metabolites. It will be used in randomized placebo-controlled trials examining the effect of cannabis on driving performance and improving the detection of impaired drivers as well as other studies.

**Acknowledgments:** The authors would like to thank Waters Corporation for their support, training, and technical assistance throughout this project.

**Author contributions:** All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

**Research funding:** This work was supported by the State of California via the Medical Marijuana Regulation and Safety Act (Assembly Bill 266). Additional support was provided by the Center for Medicinal Cannabis Research at the University of California, San Diego, which receives support from the Control, Regulate, and Tax Adult Use of Marijuana Act (California Proposition 64) and philanthropic gifts from the Wholistic Research and Education Foundation.

**Employment or leadership:** None declared.

**Honorarium:** None declared.

**Competing interests:** The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

## References

1. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Collection: Reports funded by National Institutes of Health. Washington, DC: National Institutes of Health, 2017.
2. Ebbert JO, Scharf EL, Hurt RT. Medical cannabis. *Mayo Clin Proc* 2018;93:1842–7.
3. Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. *Curr Opin Psychol* 2019;30:98–102.
4. Kelley-Baker T, Berning A, Ramirez A, Lacey JH, Carr K, Waehrer G, et al. 2013–2014 National Roadside Study of alcohol and drug use by drivers: drug results (Report No. DOT HS 812 411). Washington, DC: National Highway Traffic Safety Administration, 2017.
5. Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition – a systematic review. *Biol Psychiatry* 2016;79:557–67.
6. Compton R. Marijuana-impaired driving – a report to congress (DOT HS 812 440). Washington, DC: National Highway Traffic Safety Administration, 2017.
7. Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. *Drug Alcohol Depend* 2004;73:109–19.
8. Biecheler M-B, Peytavin J-F, the SAMG, Facy F, Martineau H. SAM survey on “drugs and fatal accidents”: search of substances consumed and comparison between dInvolved under the influence of alcohol or cannabis. *Traffic Injury Prev* 2008;9:11–21.
9. Logan B, Kacinko SL, Beirness DJ. An evaluation of data from drivers arrested for driving under the influence in relation to *per se* limits for cannabis. AAA Foundation for Traffic Safety, 2016. <https://aaafoundation.org/wp-content/uploads/2017/12/EvaluationOfDriversInRelationToPerSeReport.pdf>.
10. Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney GR, et al. Effect of blood collection time on measured delta9-tetrahydrocannabinol concentrations: implications for driving interpretation and drug policy. *Clin Chem* 2016;62:367–77.
11. Schwoppe DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance, subjective and physiological effects and whole blood Delta(9)-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. *J Anal Toxicol* 2012;36:405–12.
12. Hartman RL, Huestis MA. Cannabis effects on driving skills. *Clin Chem* 2013;59:478–92.
13. Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on *per se* drugged driving laws. *Clin Chem* 2013;59:519–26.

14. Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. *Clin Chem* 2016;62:1579–92.
15. Scheidweiler KB, Schwoppe DM, Karschner EL, Desrosiers NA, Gorelick DA, Huestis MA. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. *Clin Chem* 2013;59:1108–17.
16. Himes SK, Scheidweiler KB, Beck O, Gorelick DA, Desrosiers NA, Huestis MA. Cannabinoids in exhaled breath following controlled administration of smoked cannabis. *Clin Chem* 2013;59:1780–9.
17. Sobolesky PM, Smith BE, Hubbard JA, Stone J, Marcotte TD, Grelotti DJ, et al. Validation of a liquid chromatography-tandem mass spectrometry method for analyzing cannabinoids in oral fluid. *Clin Chim Acta* 2019;491:30–8.
18. Rudzki PJ, Gniadzowska E, Bus-Kwasnik K. Quantitative evaluation of the matrix effect in bioanalytical methods based on LC-MS: a comparison of two approaches. *J Pharm Biomed Anal* 2018;155:314–9.
19. Hadener M, Weinmann W, Schurch S, König S. Development of a rapid column-switching LC-MS/MS method for the quantification of THCCOOH and THCCOOH-glucuronide in whole blood for assessing cannabis consumption frequency. *Anal Bioanal Chem* 2016;408:1953–62.
20. König S, Aebi B, Lanz S, Gasser M, Weinmann W. On-line SPE LC-MS/MS for the quantification of Delta9-tetrahydrocannabinol (THC) and its two major metabolites in human peripheral blood by liquid chromatography tandem mass spectrometry. *Anal Bioanal Chem* 2011;400:9–16.
21. Palazzoli F, Citti C, Licata M, Vilella A, Manca L, Zoli M, et al. Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Delta(9)-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD. *J Pharm Biomed Anal* 2018;150:25–32.
22. Schwoppe DM, Scheidweiler KB, Huestis MA. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem* 2011;401:1273–83.
23. Teixeira H, Verstraete A, Proenca P, Corte-Real F, Monsanto P, Vieira DN. Validated method for the simultaneous determination of Delta9-THC and Delta9-THC-COOH in oral fluid, urine and whole blood using solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionization. *Forensic Sci Int* 2007;170:14–55.
24. Tiscione NB, Miller R, Shan X, Sprague J, Yeatman DT. An efficient, robust method for the determination of cannabinoids in whole blood by LC-MS-MS. *J Anal Toxicol* 2016;40:639–48.
25. Fell JC, Scherer M. Estimation of the potential effectiveness of lowering the blood alcohol concentration (BAC) limit for driving from 0.08 to 0.05 grams per deciliter in the United States. *Alcohol Clin Exp Res* 2017;41:2128–39.
26. Lynch KL, Luo YR, Hooshfar S, Yun C. Correlation of breath and blood Delta(9)-tetrahydrocannabinol concentrations and release kinetics following controlled administration of smoked cannabis. *Clin Chem* 2019. pii: clinchem.2019.304501. doi: 10.1373/clinchem.2019.304501 [Epub ahead of print].
27. Coucke L, Massarini E, Ostijn Z, Beck O, Verstraete AG. Delta(9)-Tetrahydrocannabinol concentrations in exhaled breath and physiological effects following cannabis intake – a pilot study using illicit cannabis. *Clin Biochem* 2016;49:1072–7.
28. Beck O, Sandqvist S, Dubbelboer I, Franck J. Detection of Delta9-tetrahydrocannabinol in exhaled breath collected from cannabis users. *J Anal Toxicol* 2011;35:541–4.
29. Luo YR, Yun C, Lynch KL. Quantitation of cannabinoids in breath samples using a novel derivatization LC-MS/MS assay with ultra-high sensitivity. *J Anal Toxicol* 2019;43:331–9.
30. Garzinsky AM, Walpurgis K, Krug O, Thevis M. Does oral fluid contribute to exhaled breath samples collected by means of an electret membrane? *Drug Test Anal* 2019. doi: 10.1002/dta.2597. [Epub ahead of print].
31. Sorensen LK, Hasselstrom JB. Sensitive determination of cannabinoids in whole blood by LC-MS-MS after rapid removal of phospholipids by filtration. *J Anal Toxicol* 2017;41:382–91.
32. Scheidweiler KB, Newmeyer MN, Barnes AJ, Huestis MA. Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. *J Chromatogr A* 2016;1453:34–42.
33. Hanisch S, Paulke A, Toennes SW. 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol glucuronide exhibits acyl-migration isomers. *J Pharm Biomed Anal* 2017;146:261–5.

**Supplementary Material:** The online version of this article offers supplementary material (<https://doi.org/10.1515/cclm-2019-0600>).